Data Sheet (Cat.No.T15454)

TargetMol
A DRUG SCREENING EXPERT

GW843682X

Chemical Properties



CAS No.:	660868-91-7
Formula:	C22H18F3N3O4S
Molecular Weight:	477.46
Appearance:	N/A
Storage:	0-4℃ for short term (days to weeks), or -20℃ for long term (months).

Biological Description

Description	GW843682X is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s: 2.2 nM and 9.1 nM, respectively). It is also >100-fold selective against ~30 other kinases.
Targets(IC_{50})	PLK1: 2.2 nM PLK3: 9.1 nM PDGFR1β: 160 nM VEGFR2: 360 nM Aurora A: 4800 nM CDK2/cyclin A: 7600 nM

Solubility Information

Solubility	DMSO: 33.33 mg/mL (69.81 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.094 mL	10.472 mL	20.944 mL
5 mM	0.419 mL	2.094 mL	4.189 mL
10 mM	0.209 mL	1.047 mL	2.094 mL
50 mM	0.042 mL	0.209 mL	0.419 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 ℃ for 6 months; - 20 ℃ for 1 month. Please use it as soon as possible.

Reference

1. Lansing TJ, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther. 2007 Feb;6(2):450-9. Epub 2007 Jan 31.

2. Didier C, et al. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia. Eur J Pharmacol. 2008 Sep 4;591(1-3):102-5.

3. Ikezoe T, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia. 2009 Sep;23(9):1564-76.

Inhibitors · Natural Compounds · Compound Libraries

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481